The "Market Spotlight: Tuberculosis (TB)" report has been added to ResearchAndMarkets.com's offering.
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.
The majority of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.
High-impact upcoming events for drugs in the TB space comprise topline Phase II trial results for GSK3036656 and a meeting with the FDA for SPR720.
The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.3%, and the average probability a drug advances from Phase III is 62.6%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
There have been 17 licensing and asset acquisition deals involving TB drugs during 2015-20. The largest deal was the $74.5m transaction agreement in 2018 between Evotec and Sanofi, pursuant to which Evotec will integrate Sanofi's infectious disease unit into its organization and in-license the majority of Sanofi's infectious disease research portfolio, including TB.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 75% of trials in Phase I-II, and only 25% in Phase III-IV.
South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia
Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.
Key Topics Covered:
RECENT EVENTS AND ANALYST OPINION
Pretomanid for TB (June 6, 2019)
Pretomanid for TB (June 4, 2019)
Pretomanid for TB (April 18, 2019)
Pretomanid for TB (October 26, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
Global Approvals Snapshot: November 2019
Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions
Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant TB
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Pfizer Deal Covers Sutezolid For TB
Deals Shaping The Medical Industry, December 2019
Shionogi, Hsiri Expand Mycobacterial R&D Pact
BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
For more information about this report visit https://www.researchandmarkets.com/r/6jyfh5
View source version on businesswire.com: https://www.businesswire.com/news/home/20200703005084/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900